CN115671209A - Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method - Google Patents
Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method Download PDFInfo
- Publication number
- CN115671209A CN115671209A CN202211135623.0A CN202211135623A CN115671209A CN 115671209 A CN115671209 A CN 115671209A CN 202211135623 A CN202211135623 A CN 202211135623A CN 115671209 A CN115671209 A CN 115671209A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- diabetic foot
- tissue
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of a composition in preparing a medicament for treating diabetic foot, wherein the composition comprises the following raw materials: musk, borneol, cinnabar, realgar, moleplant seed cream, euphorbia pekinensis, chinese gall and edible tulip, and relates to the technical field of medicines. Experiments on the composition influencing a diabetic foot mouse show that the composition can obviously promote the healing of an ulcer wound of the diabetic foot mouse, promote the capillary angiogenesis of the tissue of the ulcer wound, and promote the angiogenesis of granulation tissue of the wound by up-regulating the expression of VEGF and TGF-beta 1 proteins in the tissue of the ulcer wound, so that the composition can relieve the symptoms of the diabetic foot, has a key effect in regulating and controlling diabetic foot, provides a new medicine selection for the future treatment of the diabetic foot, and has wide development and application values.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of a composition in preparing a medicine for treating diabetic foot.
Background
The diabetic foot refers to foot infection of diabetic patients caused by combined neuropathy and peripheral vascular lesions of different degrees, and is usually related to ischemia, neuropathy, bacterial invasion infection and the like. The diabetic foot is one of the common complications of diabetes, and along with the increasing of the prevalence rate of the diabetes year by year, the sick population of the diabetic foot also increases year by year, the proportion of the diabetic foot patients in the diabetic patients can reach 60% -80%, the disability rate and the fatality rate of the diabetic foot patients are high, and the diabetic foot patients cause great harm to the health and life safety of the patients. The pathophysiological mechanisms of the diabetic foot comprise neuropathy, vasculopathy, immunity reduction and the like, so that the diabetic patient is easy to suffer from foot infection. The diabetic foot is classified into nervous ulcer, ischemic ulcer and nerve-ischemic ulcer according to the cause of ulcer, and classified into diabetic foot wet gangrene, diabetic foot dry gangrene and diabetic mixed gangrene according to the gangrene condition of a patient.
At present, the treatment methods of diabetic foot include debridement, negative pressure wound treatment, hyperbaric oxygen therapy, epidermal growth factor, photodynamic therapy and the like. The method for treating diabetic foot is complex, and has the conditions of long treatment period, high treatment cost, slow effect, poor safety and the like.
The compound has obvious side effects on treating the diabetic foot, and can cause other adverse effects, so that the problem of urgent need to be solved for treating the diabetic foot by searching a composition with less adverse reactions and a treatment method which is convenient to operate.
Chinese patent CN114404590A "use of TGF-beta inhibitor in preparation of medicine for treating diabetic foot" discloses that by adding the TGF-beta inhibitor obtained by screening into a culture medium, endothelial cells are domesticated and cultured to obtain function-enhanced endothelial cells, and the endothelial cells are prepared into a cell preparation for treating diabetic foot. Has obvious treatment effect on promoting the regeneration of the bypass blood vessels of the diabetic foot patients and improving the blood circulation of the affected limbs. But the preparation method is more complicated.
Chinese patent CN103271930A discloses a medicine composition for treating diabetic foot and acral skin lesion caused by diabetes and a preparation method thereof. The pharmaceutical composition of the patent is an ointment prepared by mixing prostaglandin E1 and monosialotetrahexosylganglioside in a proper proportion and adding auxiliary materials in a proper proportion. Prostaglandins can improve microcirculation and dilate blood vessels. The monosialotetrahexosylganglioside can promote nerve cell differentiation and synapse formation, and has neurotrophic and protective effects on nervous systems. The pharmaceutical composition prepared from the two active ingredients has a synergistic effect on treating diabetic foot. But long-term use may cause some side effects to the body.
Therefore, in order to better treat the diabetic foot, the traditional Chinese medicine composition prepared from natural traditional Chinese medicines and having small toxic and side effects, good safety and obvious curative effect is developed and researched, and is extremely important for treating the diabetic foot. The invention discloses application of a composition in preparing a medicament for treating diabetic foot. The invention has simple manufacturing process, convenient operation, low cost and strong safety, and has better treatment effect on the diabetic foot.
Disclosure of Invention
The invention aims to provide application of a composition in preparing a medicament for treating diabetic foot. In order to realize the purpose of the invention, the technical scheme of the invention is as follows:
in one aspect, the invention provides an application of a composition in preparing a medicament for treating diabetic foot, wherein the composition comprises the following raw materials: moschus, borneolum Syntheticum, cinnabaris, realgar, semen Euphorbiae Humifusae cream, radix Knoxiae, galla chinensis, and Pseudobulbus Cremastrae seu pleiones.
Preferably, the composition comprises the following raw materials in parts by weight: 20-40 parts of musk, 10-20 parts of borneol, 50-70 parts of cinnabar, 80-100 parts of realgar, 80-100 parts of moleplant seed cream, 120-150 parts of euphorbia pekinensis, 160-200 parts of Chinese gall and 160-200 parts of edible tulip.
Further preferably, the composition comprises the following raw materials in parts by weight: 25-35 parts of musk, 12-18 parts of borneol, 55-65 parts of cinnabar, 85-95 parts of realgar, 85-95 parts of moleplant seed cream, 130-140 parts of euphorbia pekinensis, 170-190 parts of Chinese gall and 170-190 parts of edible tulip.
Most preferably, the composition comprises the following raw materials in parts by weight: 30 parts of musk, 15 parts of borneol, 60 parts of cinnabar, 90 parts of realgar, 90 parts of moleplant seed cream, 135 parts of euphorbia pekinensis, 180 parts of Chinese gall and 180 parts of edible tulip;
most preferably, the composition is Yushusan.
Preferably, the symptoms of the diabetic foot include one or more of foot neuropathy, foot vasculopathy, deep tissue destruction, weak tissue repair capability, foot soft tissue deformity, bone joint system destruction, plantar hypertension, arthrosis, poor blood supply, foot ulcer, ischemia, infection, gangrene, and tissue inflammation.
Further preferably, the symptoms of the diabetic foot include one or more of poor blood supply, foot ulcers.
Preferably, the composition is used for relieving the symptoms of the diabetic foot by one or more of promoting healing of an ulcer wound of the diabetic foot, promoting capillary vessel neogenesis at an ulcer wound tissue and up-regulating protein expression of an angiogenesis index in the ulcer wound tissue.
Further preferably, the composition is used for relieving the symptoms of the diabetic foot by up-regulating the protein expression of angiogenesis indicators VEGF and TGF-beta 1 in the tissues of the ulcer wound.
Preferably, the composition is used in combination with a pharmaceutically acceptable adjuvant selected from one or more of vaseline, stearic acid, glyceryl monostearate, glycerol, sodium lauryl sulfate, rosin, liquid paraffin, beeswax, lanolin, stearyl alcohol; the mass ratio of the composition to the auxiliary materials is 1: (1-5);
further preferably, the auxiliary material is vaseline; the mass ratio of the composition to the auxiliary materials is 1: (1.5-4).
Preferably, the pharmaceutical dosage form of the composition is a cold pack or a plaster.
Preferably, the preparation method of the composition comprises the following steps:
(1) Pulverizing Cinnabaris and Realgar to 100-300 mesh, pulverizing radix Knoxiae, galla chinensis and Pseudobulbus Cremastrae seu pleiones to 10-100 mesh, and pulverizing Moschus, borneolum Syntheticum and Euphorbiae Lathyridis semen to 10-100 mesh;
(2) Grinding the above powders, sieving, and mixing to obtain composition powder.
The invention has the beneficial effects that:
(1) The composition disclosed in the invention can effectively promote the healing of the ulcer wound of the diabetic foot.
(2) The composition disclosed by the invention can obviously promote angiogenesis in the granulation tissue of the foot ulcer wound of a diabetic mouse.
(3) The composition disclosed by the invention can promote the angiogenesis of wound granulation tissues and reduce wound angiogenesis disorders to relieve diabetic foot symptoms by up-regulating the expression of VEGF and TGF-beta 1 proteins in ulcer wound tissues.
(4) The composition disclosed in the invention can provide a new candidate drug for the treatment of diabetic foot.
Drawings
FIG. 1 is a graph showing the effect of Yushusan of example 4 on the expression of VEGF and TGF-beta 1 proteins on the surface of a foot ulcer in a diabetic mouse, in which, compared with a blank group, * p＜0.05， ** p is less than 0.01; in comparison with the set of models, # p is less than 0.05; comparing the Yushu powder high-dose group with the musk borneol powder high-dose group, △ p＜0.05。
Detailed Description
The present invention will be further explained with reference to specific examples in order to make the technical means, the technical features, the technical objectives and the effects of the present invention easier to understand, but the following examples are only preferred embodiments of the present invention, and not all embodiments of the present invention. Based on the embodiments in the implementation, other embodiments obtained by those skilled in the art without any creative efforts belong to the protection scope of the present invention. In the following examples, unless otherwise specified, all the operations were performed by conventional methods, all the equipments were performed by conventional methods, and the materials of the equipments used in the respective examples were the same.
In some embodiments of the invention, the composition used is Yushu powder, which consists of musk 30g, borneol 15g, cinnabar 60g, realgar 90g, moleplant seed cream 90g, euphorbia pekinensis 135g, gallnut 180g and edible tulip 180 g.
Example 1 drug formulation and animal model establishment
1. Material
1.1 Experimental animals
100 SPF-level Kunming mice are male, 7-8 weeks old and 18-22g in body weight. Feeding in SPF animal house, maintaining room temperature at 20-22 deg.C, humidity at 45-55%, and sunlight exposure time of 12 hr. Except for the condition that the model is made and the fasting blood sugar is detected, the experimental mice drink water freely and change the padding every day.
1.2 Experimental reagents
Streptozotocin (STZ) was purchased from Shanghai assist feather Biotech Co., ltd. (batch No.: 60243Q60, specification: 100 mg/count); yushusan (Lei Yun, pharmaceutical products of pharmaceutical industry group ltd, national standard Z32020488, lot number TA 19001); detoxicating and promoting granulation paste (Guangxi Zhuang autonomous region Huahong pharmaceutical industry GmbH, kagao Yao Z45020400, batch No. 20210710); musk; borneol; vaseline.
1.3 pharmaceutical formulation
Preparation of 20% Yushusan preparation:
0.6g of Yushu powder is added with 2.4g of vaseline and mixed evenly to prepare 20 percent Yushu powder preparation.
Preparation of 40% Yushusan preparation:
weighing 1.2g of Yushu powder, adding 1.8g of vaseline, and mixing to obtain 40% Yushu powder preparation.
After the preparation is finished, the mixture is stored in a refrigerator at 4 ℃ and is prepared once in 3 days.
1.154% musk borneol powder preparation:
0.1g of musk borneol powder is weighed, 8.56g of Vaseline is added to be mixed evenly, and 1.154 percent of musk borneol powder is prepared respectively.
Preparation of 2.31% musk borneol powder:
weighing 0.2g of musk borneol powder, adding 8.46g of vaseline, and mixing uniformly to prepare 2.31% musk borneol powder respectively.
2. Molding and method
After being adaptively fed for one week, 100 SPF-level Kunming mice are randomly divided into two groups according to body weight, 8 blank groups and 92 model groups. Fasting is not forbidden for more than 12h before modeling, a modeled mouse is subjected to single intraperitoneal injection of streptozotocin STZ (80 mg/kg), fasting blood glucose is detected after 72h, fasting blood glucose of more than 16.7mmol/L can be regarded as successful modeling of a diabetes model, fasting blood glucose is continuously detected at 7d and 14d after modeling is finished respectively, mice with the fasting blood glucose not reaching the standard are removed, and 48 mice of a modeling group with qualified blood glucose are selected to be randomly divided into 6 groups according to blood glucose and weight: model group, detoxification granulation promoting ointment group, 20% Yushu powder group, 40% Yushu powder group, 1.154% Musk borneol powder group and 2.31% Musk borneol powder group, wherein each group comprises 8.
Both blank mice and diabetic model mice were subjected to foot ulcer modeling: after fasting and no water supply for 12h, 10% chloral hydrate is injected into the abdominal cavity for anesthesia, the injection volume is 0.33ml/10g, a disposable skin biopsy punch with the diameter of 5mm is used for punching the back of the lower limb of a mouse, and a single-round full-thickness skin wound (the diameter is about 5 mm) is manufactured by assisting surgical scissors. And the wound was stimulated with a cotton ball full of 50% glacial acetic acid three times in 24h after the wound was opened. And (3) observing the wound which is stimulated by glacial acetic acid to generate necrosis to form severe infection and difficult-to-heal ulcer, and judging that the molding and repeated engraving of the diabetic skin ulcer mouse are successful when the characteristics of the diabetic skin ulcer are met. After the model building is successful, the corresponding medicine is applied to each group, the thickness of the covered wound surface is about 0.3mm, vaseline with the same volume is applied to the wound surface for the control group and the model group, the medicine is changed for 1 time every day, the wound is cleared by physiological liquid medicine before the medicine is changed, the medicine is continuously applied for 14 days, the wound healing condition is observed every day, the photographing is carried out for 2 times every week, the ulcer wound surface area is measured by adopting Image-Pro Plus 6.0 Image analysis software, and the wound healing rate is calculated. The details of the grouping and administration are shown in table 1.
TABLE 1 animal grouping administration table
Example 2 Effect of Yushusan on diabetic mouse foot ulcer wound healing Rate
1. Test method
On 7 th and 14 th days after administration, after residual medicines are removed by using physiological saline, foot ulcers of each group of mice are photographed at the same distance, the area of the ulcer wound surface is determined by using Image-Pro Plus 6.0 Image analysis software, and the wound surface healing rate is calculated.
Wound healing rate = [ (original wound area-non-healed wound area)/original wound area ] × 100%
2. Results
The results are shown in Table 2, and the comparison of ulcer areas of the mice in each group has no significant difference (p is more than 0.05) after the model is made. After 7 days of administration, the area of the ulcer wound surface of the model group mouse is obviously higher than that of the blank group (p is less than 0.01); compared with the model group, the wound area of each administration mouse is reduced, wherein the wound area of the ulcer of the mice in the detoxification granulation-promoting foot group, the Yushu powder low dose group and the Yushu powder high dose group is significantly different (p is less than 0.01). After 14 days of administration, the area of the ulcer wound surface of the model group mouse is still higher than that of the blank group, the healing rate of the ulcer wound surface is lower than that of the blank group, and the difference has statistical significance (p is less than 0.01); compared with the wound surface area of a model group mouse, the ulcer wound surface area of each administration group mouse is reduced, wherein the reduction of the detoxification tissue regeneration promoting ointment group, the reduction of the Yushusan low dose and the reduction of the Yushusan high dose have significant difference (p is less than 0.05-0.01); compared with the ulcer healing rate of a model group of mice, the ulcer healing rate of each administration mouse is increased, wherein the increase of the detoxification tissue regeneration ointment group, the increase of the lower dose of the Yujing powder and the increase of the higher dose of the Yujing powder have significant differences (p is less than 0.05-0.01).
In addition, the ulcer wound area of the Yushu powder high-dose group mice after 7 days of administration is obviously smaller than that of the Musk borneol powder high-dose group (p is less than 0.05); after 14 days of administration, the wound area of the Yushu group mice is obviously smaller than that of the Musk borneol powder group with equal dosage (p is less than 0.05), and the wound healing rate of the Yushu group mice is obviously higher than that of the Musk borneol powder group with equal dosage (p is less than 0.05-0.01).
The result shows that the positive medicine detoxification granulation-promoting ointment and the 20 percent and 40 percent of Yushusan can obviously promote the healing of foot ulcers of diabetic mice, and the effect of promoting wound healing of the 40 percent of Yushusan on the same side of the positive medicine detoxification granulation-promoting ointment. In addition, the musk and borneol powder prepared by laboratories can also promote the healing of diabetic ulcer wounds to a certain extent, but the effect is not obvious, and the effect of the Yuzhu powder for promoting the healing of wounds is obviously better than that of the musk and borneol powder with equal dosage.
TABLE 2 influence of Yushu powder on the healing of ulcer wound surface area (mm) 2 ,
n＝8)
Note: in comparison with the blank set, the results, * p＜0.05， ** p is less than 0.01; in comparison with the set of models, # p＜0.05， ## p is less than 0.01; comparing the Yushu powder low-dose group with the musk borneol powder low-dose group, @ p is less than 0.05; comparing the Yushu powder high-dose group with the musk borneol powder high-dose group, △ p＜0.05， △△ p＜0.01。
example 3 Effect of Yushusan on diabetic mouse foot ulcer tissue neovascularization
1. Experimental methods
Each group selected 3 mice, collected ulcer wound granulation tissues, were soaked in 10% neutral formalin for fixation, paraffin-embedded, sectioned, PCNA immunohistochemical staining was performed to observe the number of new capillaries, and 3 fields of each tissue section at random for wound edge observation were averaged.
2. Results
The condition of the wound surface neovascularization is observed by carrying out immunohistochemical staining on ulcer wound surface tissues and PCNA protein. The result shows that 14 days after the administration, the number density of the new capillaries in the foot ulcer wound granulation tissue of the model group mice is obviously lower than that of the blank group (p is less than 0.01); compared with the model group, the density of the new blood vessels in the granulation tissue of the ulcer wound surface of the mice of each administration group is increased, wherein the increase of the detoxification granulation ointment group, the increase of the lower dose of the Yushu powder and the increase of the higher dose of the Yushu powder have significant difference (p is less than 0.05-0.01). In addition, the angiogenesis density in the tissue of the ulcer wound surface of the Yushusan group mouse is obviously higher than that of the musk borneol group with equal dosage (p is less than 0.05). The positive medicine detoxifying and tissue regeneration promoting ointment and 20 percent and 40 percent of Yushu powder can obviously promote angiogenesis in the granulation tissue of the foot ulcer wound of the diabetic mouse, and the effect of the 40 percent of Yushu powder is the same as that of the positive medicine detoxifying and tissue regeneration promoting ointment. The musk borneol powder prepared by a laboratory can also promote angiogenesis in the granulation tissue of the foot ulcer wound of a diabetic mouse to a certain extent, but the effect is not obvious, and the effect of the musk borneol powder for promoting angiogenesis of the foot ulcer wound of the mouse is obviously higher than that of a musk borneol group with the same dosage. The results are shown in Table 3.
TABLE 3 mouse ulcer wound neocapillary density (n =3,x + -SD)
Note: in comparison with the blank set, the results, * p＜0.05， ** p is less than 0.01; in comparison with the set of models, # p＜0.05， ## p is less than 0.01; comparing the Yushu powder low-dose group with the musk borneol powder low-dose group, @ p is less than 0.05; comparing the Yushu powder high-dose group with the musk borneol powder high-dose group, △ p＜0.05。
example 4 angiogenesis indicators VEGF, TGF-beta 1 protein expression levels in diabetic mouse foot ulcer tissue
Vascular Endothelial Growth Factor (VEGF) is a mitotic stimulator and chemokine of endothelial cells and has the effects of promoting revascularization, increasing vascular permeability, and protecting neurons. During wound repair, VEGF can promote wound angiogenesis by stimulating endothelial cell growth, and can also participate in angiogenesis by secreting various angiogenic factors such as VEGF-R, basic fibroblast growth factor, angiopoietin-2 and angiopoietin-1, etc. Therefore, VEGF is a main effector molecule for neovascularization of granulation tissues of ulcer wounds, and the expression level of VEGF in the wounds is closely related to neovascularization and wound healing. Transforming growth factor beta 1 (TGF-beta 1) is a multi-potent growth factor that can regulate the growth and differentiation of cells by stimulating the secretion of extracellular matrix, promote angiogenesis, and play a promoting role in wound repair.
1. Test method
The blank group, the model group, the detoxifying and tissue regeneration promoting paste group, the Yushusan high-dose group and the musk borneol powder high-dose group are respectively selected from 3 mouse wound surfaces at random, ground into components after being quickly frozen by liquid nitrogen, added with a proper amount of PBS to prepare tissue homogenate, and the protein expression conditions of VEGF and TGF-beta 1 in the ulcer tissue homogenate are detected by adopting an immune protein blotting method.
2. Results
The expression levels of VEGF and TGF-beta 1 protein in the foot ulcer wound tissue of the mouse are detected by adopting an immune western blotting method, and the result shows that the expression levels of VEGF and TGF-beta 1 in the ulcer wound granulation tissue of the mouse in the model group are obviously reduced (p is less than 0.05) compared with that in the blank group; compared with the model group, the expression levels of VEGF and TGF-beta 1 proteins in the wound granulation tissues of the mice in the detoxification tissue regeneration ointment group, the Yujing powder high-dose group and the Musk borneol powder high-dose group are increased on average, wherein the VEGF expression of the detoxification tissue regeneration ointment and the expression up-regulation of VEGF and TGF-beta 1 in the Yujing powder high-dose group are respectively different in significance (p is less than 0.05); in addition, the effect of up-regulating VEGF and TGF-beta 1 protein expression by the Yujing powder high dose is stronger than that of the musk borneol high dose group, wherein the TGF-beta 1 protein level of the Yujing powder high dose group is obviously higher than that of the musk borneol high dose group (p is less than 0.05). The detoxifying and tissue regeneration promoting ointment and the high-dose Yushu powder can promote the expression of VEGF and TGF-beta 1 in ulcer wound tissues, and the effect of the high-dose Yushu powder for up-regulating TGF-beta 1 is stronger than that of the positive medicine detoxifying and tissue regeneration promoting ointment. The high-dose musk borneol powder can slightly up-regulate the expression of VEGF in the ulcer wound surface, but has no obvious regulation effect on TGF-beta 1. The results are shown in FIG. 1. In fig. 1, A is blank group, B is model group, C is detoxifying and tissue regeneration promoting ointment group, D is Yujing powder high dose group, and E is musk borneol powder high dose group.
The experimental results of the inventor show that the Yujing powder external preparations prepared from vaseline with the concentration of 20% and 40% can obviously promote the healing of the ulcer wound of a diabetic mouse, relieve the inflammation of the ulcer wound, promote the capillary angiogenesis of the tissue of the ulcer wound, and promote the angiogenesis of the granulation tissue of the wound through up-regulating the expression of VEGF and TGF-beta 1 proteins in the tissue of the ulcer wound, reduce the angiogenesis disorder of the wound, improve the blood circulation of the wound tissue and promote the healing of the diabetic ulcer wound, while the musk borneol powder with the same concentration, which is self-prepared by a laboratory, can slightly promote the healing and the angiogenesis of the foot ulcer wound of the diabetic mouse, but the effect is not obvious, and the expression of angiogenesis-related proteins has no obvious regulation effect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The application of a composition in preparing a medicament for treating diabetic foot is characterized in that the composition comprises the following raw materials: moschus, borneolum Syntheticum, cinnabaris, realgar, semen Euphorbiae Humifusae cream, radix Knoxiae, galla chinensis, and Pseudobulbus Cremastrae seu pleiones.
2. The use of claim 1, wherein the composition comprises the following raw materials in parts by weight: 20-40 parts of musk, 10-20 parts of borneol, 50-70 parts of cinnabar, 80-100 parts of realgar, 80-100 parts of moleplant seed cream, 120-150 parts of euphorbia pekinensis, 160-200 parts of Chinese gall and 160-200 parts of edible tulip.
3. The use of claim 2, wherein the composition comprises the following raw materials in parts by weight: 25-35 parts of musk, 12-18 parts of borneol, 55-65 parts of cinnabar, 85-95 parts of realgar, 85-95 parts of moleplant seed cream, 130-140 parts of euphorbia pekinensis, 170-190 parts of Chinese gall and 170-190 parts of edible tulip.
4. The use of claim 3, wherein the composition comprises the following raw materials in parts by weight: 30 parts of musk, 15 parts of borneol, 60 parts of cinnabar, 90 parts of realgar, 90 parts of moleplant seed cream, 135 parts of knoxia root, 180 parts of Chinese gall and 180 parts of edible tulip.
5. The use of claim 4, wherein said composition is Yushusan.
6. The use of claim 1, wherein the symptoms of the diabetic foot include one or more of neuropathy of the foot, vasculopathy of the foot, deep tissue destruction, weak tissue repair, malformation of soft tissue of the foot, destruction of the osteoarticular system, plantar hypertension, arthropathy, poor blood supply, foot ulcers, ischemia, infection, gangrene, and tissue inflammation.
7. The use of claim 1, wherein the composition is for alleviating the symptoms of a diabetic foot by one or more of promoting healing of an ulcerative wound in the diabetic foot, promoting capillary neogenesis at the tissue of the ulcerative wound, and upregulating protein expression of an indicator of angiogenesis in the tissue of the ulcerative wound.
8. The use of claim 7, wherein the composition is for alleviating the symptoms of diabetic foot by up-regulating the expression of the angiogenesis indicators VEGF, TGF- β 1 proteins in the tissue of the ulcerated wound.
9. The use according to claim 1, wherein the composition is used in combination with a medically acceptable adjuvant, the mass ratio of composition to adjuvant being 1: (1-5);
preferably, the mass ratio of the composition to the auxiliary materials is 1: (1.5-4).
10. Use according to any one of claims 1 to 9, wherein the pharmaceutical dosage form of the composition is a cold pack or a plaster.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211135623.0A CN115671209A (en) | 2022-09-19 | 2022-09-19 | Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211135623.0A CN115671209A (en) | 2022-09-19 | 2022-09-19 | Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671209A true CN115671209A (en) | 2023-02-03 |
Family
ID=85061945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211135623.0A Pending CN115671209A (en) | 2022-09-19 | 2022-09-19 | Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671209A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116808097A (en) * | 2023-06-30 | 2023-09-29 | 云南中医药大学 | Euphorbia pekinensis extract with hypoglycemic activity and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364539A (en) * | 2001-01-11 | 2002-08-21 | 杨孟君 | Nano Yushusan medicine and its preparing method |
-
2022
- 2022-09-19 CN CN202211135623.0A patent/CN115671209A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364539A (en) * | 2001-01-11 | 2002-08-21 | 杨孟君 | Nano Yushusan medicine and its preparing method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116808097A (en) * | 2023-06-30 | 2023-09-29 | 云南中医药大学 | Euphorbia pekinensis extract with hypoglycemic activity and application thereof |
| CN116808097B (en) * | 2023-06-30 | 2024-02-20 | 云南中医药大学 | Euphorbia pekinensis extract with hypoglycemic activity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692204B (en) | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof | |
| CN102139033B (en) | Chinese medicinal composition for treating skin wound of pregnant woman after cesarean section | |
| CN115671209A (en) | Medicine and food dual purpose Chinese medicinal product for treating diabetic foot and its manufacturing method | |
| CN101703651B (en) | Medicament for treating diabetic gangrene | |
| CN102100735B (en) | Medicinal composition for treating skin diseases | |
| CN107951904B (en) | Adipose-derived mesenchymal stem cell medicine and preparation method and application thereof | |
| CN106822377B (en) | Compound osteitis cataplasm patch and preparation method thereof | |
| CN107137471A (en) | A kind of Traditional Chinese medicine used as analgesic composition and its preparation method and application | |
| CN111759896A (en) | Pharmaceutical application of total triterpene of pawpaw | |
| CN101156849B (en) | An alepsin slow-releasing gel for promoting paradontal part reborn as well as preparation method and application | |
| CN108434301A (en) | External medicine composition and preparation method thereof for diabetes wound repair | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| RU2346696C2 (en) | Method of human immune system stimulation using activated platinoids-containing mineral, method of mineral activation and composition with immune system stimulation properties | |
| Afreen et al. | Therapeutic uses of earthworm–a review | |
| CN117298133B (en) | Application of effective ingredient formula of Guizhi sugar-gangrene in preparation of medicament for treating diabetic foot | |
| CN107335052A (en) | For treating the formulation product of diabetes | |
| CN108295178B (en) | Traditional Chinese medicine composition and traditional Chinese medicine ointment for treating refractory wound and preparation method thereof | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN105920150A (en) | Oral liquid for treating functional uterine bleeding and preparation method thereof | |
| CN105878427A (en) | Peony seed oil compound spray for curing burn and scald and preparation method | |
| CN1401350A (en) | Medicine for treating burns and scald, and producing method thereof | |
| CN114931616A (en) | Osteoporosis patch and preparation method thereof | |
| CN117617500A (en) | Functional formula powder suitable for postoperative recovery and preparation method and application method thereof | |
| Erkinjonovna | ACEXAMIC ACID DERIVATIVES AND THEIR BIOCHEMICAL EFFECTS | |
| CN113679819A (en) | Bacteriostatic agent for rapidly healing wound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |